Cancer Biomarker: refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer.
-
The human genome encodes ~21,500 proteins that are subject to reversible phosphorylation at nearly 1 million phosphosites by about 538 protein kinases and 156 protein phosphatases. Amongst ot...
Human papillomavirus (HPV) is the primary cause of cervical cancer and more than 100 types of HPV have been identified. Detection of HPV from cervical samples is associated with a 250 times...
One of the major challenges to oncology based drug discovery and development has been the limited or incremental impact that many targeted agents have exhibited in the clinic. Understanding a...
While the "Jolie effect" has refocused attention on the central role of BRCA gene analyses in the diagnosis and prevention of hereditary breast and ovarian cancer, there is a global disparity...
For the last 60 years the primary method of preventing cervical cancer in both the U.S. and Europe has been cervical cytology -- if it is negative, women are rescreen in three years and if po...
The therapeutic utility of stem cells is rooted in an understanding -- and exploitation -- of their natural role from earliest development to lifes end. Their job is first to participate in o...
Using high throughput next-generation sequencing to simultaneously search large number of genes for pathogenic mutations has numerous advantages. It decreases the pressure to narrow the dif...
When speaking of neurodegenerative diseases, average public is not made aware of the true cost that brain related disorders have on annual budget. The true impact on economy is not usually...
When speaking of neurodegenerative diseases, average public is not made aware of the true cost that brain related disorders have on annual budget. The true impact on economy is not usually...
Genome sequencing technologies have enabled a rapid expansion into understanding cancer biology, drug development, and treatment resistance. Research in our laboratory has focused on the app...
OCT 17, 2013 | 2:00 PM
C.E. CREDITS
Pancreatic cancer is the 4th most common cause of cancer deaths in the United States. Due to the aggressive nature of this cancer and the lack of biomarkers for early detection, the incidence...
The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spit...
OCT 17, 2013 | 11:00 AM
C.E. CREDITS
Curative therapy for metastatic disease in solid malignancies remains frustratingly elusive due to the long recognized problem of tumor cell heterogeneity and emergence of treatment resistant...
RNA-Seq allows the simultaneous observation of gene expression levels, mutations in the coding sequences, splice variants and gene fusions, which are especially important in cancer studies. A...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Th...
OCT 16, 2013 | 10:00 AM
C.E. CREDITS
The current paradigm of detecting established cancer (often too late) and treating routinely with cytotoxic drugs is beginning to change. Advanced technologies such as whole genome sequencin...
OCT 16, 2013 | 7:00 AM
C.E. CREDITS
With the rapid rise in the number of therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision-making, emphasizing the nee...
As Chief of Scientific Intelligence at the John Wayne Cancer Institute, Dr. Hoon interacts with external academic, industry, and government agencies to develop innovative translational rese...